Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction

[1] Zappasodi R(2018)Emerging concepts for Immune Checkpoint Blockade-Based combination therapies Cancer Cell 34 690-54

[2] Merghoub T(2020)A decade of immune-checkpoint inhibitors in cancer therapy Nat Commun 11 3801-e68

[3] Wolchok JD(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-9

[4] Robert C(2016)Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma Proc Natl Acad Sci USA 113 E7759-513

[5] Topalian SL(2019)Mechanisms of immunotherapy resistance: lessons from glioblastoma Nat Immunol 20 1100-71

[6] Hodi FS(2020)Immune Checkpoint targeted therapy in glioma: status and hopes Front Immunol 11 578877-56

[7] Brahmer JR(2020)Overcoming endocrine resistance in breast Cancer Cancer Cell 37 496-104

[8] Gettinger SN(2014)PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 568-8

[9] Smith DC(2015)PD-L1 expression as a predictive biomarker in Cancer Immunotherapy Mol Cancer Ther 14 847-72

[10] McDermott DF(2018)Nivolumab plus Ipilimumab in Lung Cancer with a high Tumor Mutational Burden N Engl J Med 378 2093-23

[1] Zappasodi R(2018)Emerging concepts for Immune Checkpoint Blockade-Based combination therapies Cancer Cell 34 690-54

[2] Merghoub T(2020)A decade of immune-checkpoint inhibitors in cancer therapy Nat Commun 11 3801-e68

[3] Wolchok JD(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-9

[4] Robert C(2016)Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma Proc Natl Acad Sci USA 113 E7759-513

[5] Topalian SL(2019)Mechanisms of immunotherapy resistance: lessons from glioblastoma Nat Immunol 20 1100-71

[6] Hodi FS(2020)Immune Checkpoint targeted therapy in glioma: status and hopes Front Immunol 11 578877-56

[7] Brahmer JR(2020)Overcoming endocrine resistance in breast Cancer Cancer Cell 37 496-104

[8] Gettinger SN(2014)PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 568-8

[9] Smith DC(2015)PD-L1 expression as a predictive biomarker in Cancer Immunotherapy Mol Cancer Ther 14 847-72

[10] McDermott DF(2018)Nivolumab plus Ipilimumab in Lung Cancer with a high Tumor Mutational Burden N Engl J Med 378 2093-23